Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 87

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 87
---
 for the accrued interest thereon) would be drawn from the Trust Account. Consequently, US$1,508,671.80 would be available to the Company. (8)A total of US$6,034,687.19 (comprising US$6,009,184.25 paid to Public Shareholders for redeeming their Public Shares and US$25,502.94 for the accrued interest thereon) would be drawn from the Trust Account. Consequently, no funds held on trust would be available to the Company. Certain United States Federal Income Tax Considerations For a discussion summarizing the material United States federal income tax considerations of an exercise of Redemption Rights, please see “ Material U.S. Federal Income Tax Considerations” below. Accounting Treatment of the Business Combination OmnigenicsAI will account for the Business Combination as a capital reorganization in accordance with IFRS as issued by the IASB. Under this method of accounting, APx will be treated as the “acquired” company for financial reporting purposes and OmngenicsAI will be the accounting “acquirer.” This determination was primarily based on the assumptions that OmngenicsAI’s shareholders will hold a majority of the voting power of the Combined Company, the Combined Company’s operations will substantially comprise the ongoing operations of OmngenicsAI, OmngenicsAI’s designees are expected to comprise a majority of the governing body of the Combined Company, and OmngenicsAI’s

11 senior management will comprise the senior management of the Combined Company. APx does not meet the definition of a “business” pursuant to IFRS3, Business Combinations, and thus, for accounting purposes, OmnigenicsAI will account for the Business Combination as a capital reorganization. The net assets of APx will be stated at historical cost, with no goodwill or other intangible assets recorded. The Business Combination will be accounted for within the scope of IFRS 2 — Share -basedPayments (“IFRS 2”). As a result, any excess of fair value of the Company Shares issued over the fair value of APx’s identifiable net assets acquired, represent compensation for the service in respect of a stock exchange listing for the Company Shares and is expensed upon consummation. For a discussion summarizing the anticipated accounting treatment of the Business Combination, please see “ Anticipated Accounting Treatment of the Business Combination.” Risk Factors In evaluating the proposals to be presented at the Special Meeting, a shareholder should carefully read this proxy statement/prospectus and especially consider the